Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia

被引：4
|
作者：
Jamy, Omer [1 ]
Lin, Karen [2 ]
Worth, Sarah [1 ]
Bachiashvili, Kimo [1 ]
Rangaraju, Sravanti [1 ]
Vachhani, Pankit [1 ]
Bhatia, Ravi [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
[2] Grandview Med Ctr, Dept Med, Birmingham, AL USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 198卷 / 03期
关键词：
VENETOCLAX;
D O I：
10.1111/bjh.18229
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E35 / E37
页数：3
相关论文
共 50 条
  • [31] Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
    Yamauchi, Takahiro
    Yoshida, Chikashi
    Usuki, Kensuke
    Takada, Satoru
    Matsumura, Itaru
    Dobashi, Nobuaki
    Miyazaki, Yasushi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Asou, Norio
    Kuroda, Junya
    Ichikawa, Satoshi
    Komatsu, Norio
    Mendes, Wellington
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Jiang, Qi
    Wei, Andrew
    Ishizawa, Kenichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (09) : 1372 - 1382
  • [32] Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases
    Wang, Na
    He, Jing
    Liu, Fang
    CHEMOTHERAPY, 2022, 67 (03) : 178 - 182
  • [33] Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML
    Ucar, M. A.
    Ozet, G.
    Koyuncu, M. B.
    Sonmez, M.
    Akidan, O.
    Ayli, M.
    Yildirim, M.
    Pehlivan, M.
    Akkurt, D. M.
    Sahin, H.
    Guvenc, B.
    Okan, V
    Tiftik, E. N.
    Akdeniz, A.
    Dincyurek, H. D.
    Gunes, A. K.
    Dagdas, S.
    Acar, H., I
    Ucar, H. K.
    Tombak, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (21) : 6557 - 6565
  • [34] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Maximilian Fleischmann
    Sebastian Scholl
    Jochen J. Frietsch
    Inken Hilgendorf
    Karin Schrenk
    Jakob Hammersen
    Florian Prims
    Christian Thiede
    Andreas Hochhaus
    Ulf Schnetzke
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3191 - 3202
  • [35] Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
    Gaut, Daria
    Burkenroad, Aaron
    Duong, Tuyen
    Feammelli, Jesse
    Sasine, Joshua
    Schiller, Gary
    LEUKEMIA RESEARCH, 2020, 90
  • [36] Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients
    Petit, C.
    Saillard, C.
    Mohty, B.
    Hicheri, Y.
    Villetard, F.
    Maisano, V.
    Charbonnier, A.
    Rey, J.
    D'Incan, E.
    Rouzaud, C.
    Gelsi-Boyer, V.
    Murati, A.
    Lhoumeau, A. C.
    Ittel, A.
    Mozziconacci, M. J.
    Alary, A. S.
    Hospital, M. -A.
    Vey, N.
    Garciaz, S.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (04) : 530 - 537
  • [37] Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study
    Ram, Ron
    Amit, Odelia
    Zuckerman, Tsila
    Gurion, Ronit
    Raanani, Pia
    Bar-On, Yael
    Avivi, Irit
    Wolach, Ofir
    ANNALS OF HEMATOLOGY, 2019, 98 (08) : 1927 - 1932
  • [38] The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
    Piccini, Matteo
    Mannelli, Francesco
    Coltro, Giacomo
    BIOENGINEERING-BASEL, 2023, 10 (05):
  • [39] Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
    Labrador, Jorge
    Saiz-Rodriguez, Miriam
    de Miguel, Dunia
    de Laiglesia, Almudena
    Rodriguez-Medina, Carlos
    Vidriales, Maria Belen
    Perez-Encinas, Manuel
    Jose Sanchez-Sanchez, Maria
    Cuello, Rebeca
    Roldan-Perez, Alicia
    Vives, Susana
    Benzo-Callejo, Gonzalo
    Colorado, Mercedes
    Garcia-Fortes, Maria
    Jose Sayas, Maria
    Olivier, Carmen
    Recio, Isabel
    Conde-Royo, Diego
    Bienert-Garcia, Alvaro
    Vahi, Maria
    Munoz-Garcia, Carmen
    Seri-Merino, Cristina
    Tormo, Mar
    Vall-llovera, Ferran
    Foncillas, Maria-Angeles
    Martinez-Cuadron, David
    Sanz, Miguel Angel
    Montesinos, Pau
    CANCERS, 2022, 14 (07)
  • [40] Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
    Fleischmann, Maximilian
    Scholl, Sebastian
    Frietsch, Jochen J.
    Hilgendorf, Inken
    Schrenk, Karin
    Hammersen, Jakob
    Prims, Florian
    Thiede, Christian
    Hochhaus, Andreas
    Schnetzke, Ulf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3191 - 3202
12345